Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Operating Leases (2023 - 2025)

Historic Operating Leases for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to $425000.0.

  • Tonix Pharmaceuticals Holding's Operating Leases fell 3928.57% to $425000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $425000.0, marking a year-over-year decrease of 3928.57%. This contributed to the annual value of $358000.0 for FY2024, which is 4335.44% down from last year.
  • Tonix Pharmaceuticals Holding's Operating Leases amounted to $425000.0 in Q3 2025, which was down 3928.57% from $492000.0 recorded in Q2 2025.
  • Tonix Pharmaceuticals Holding's Operating Leases' 5-year high stood at $898000.0 during Q2 2023, with a 5-year trough of $358000.0 in Q4 2024.
  • Moreover, its 3-year median value for Operating Leases was $632000.0 (2023), whereas its average is $645818.2.
  • Examining YoY changes over the last 5 years, Tonix Pharmaceuticals Holding's Operating Leases showed a top increase of 5909.09% in 2024 and a maximum decrease of 4335.44% in 2024.
  • Over the past 3 years, Tonix Pharmaceuticals Holding's Operating Leases (Quarter) stood at $632000.0 in 2023, then plummeted by 43.35% to $358000.0 in 2024, then rose by 18.72% to $425000.0 in 2025.
  • Its Operating Leases stands at $425000.0 for Q3 2025, versus $492000.0 for Q2 2025 and $563000.0 for Q1 2025.